London, United Kingdom
ADVANZ PHARMA positions itself as a leading global pharmaceutical firm focused on specialty, hospital, and rare disease medicines, serving a critical role in patient care by providing essential treatments worldwide. Established in 1963 and headquartered in the United Kingdom, the company offers a diverse product mix, including innovative medicines, specialty generics, biosimilars, and originator brands across numerous therapeutic areas such as hepatology, gastroenterology, and rare diseases.
The company's strategic operations span over 90 countries, underpinned by a direct commercial presence in more than 20 key markets, including Europe, the US, Canada, and Australia. They leverage an extensive network supported by a Centre of Excellence in Mumbai, India and strong global distribution partnerships.
Recently, ADVANZ PHARMA attracted investment from Nordic Capital and the Ontario Teachers' Pension Plan in a Post-IPO Equity round dated 26 February 2024, solidifying confidence in its growth trajectory and commercial collaboration capabilities.
